Organisation paid for research Program year 2025 Source: CMS Open Payments

HCA Research Institute LLC

Neither a doctor nor a teaching hospital

Research payments

$10,130,253

2,003 payments

Through program year 2025, HCA Research Institute LLC is reported as receiving $10,130,253 in research payments, across 2,003 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $6,396,183 831
2024 Research $2,542,298 732
2023 Research $1,127,014 402
2022 Research $64,759 38

Breakdown

Who paid Research payments · program years 2022–2025
  1. Abbott Laboratories $2,440,104 406 payments
  2. Biosense Webster, Inc. $1,770,007 103 payments
  3. Boston Scientific Corporation $1,468,383 370 payments
  4. Medtronic, Inc. $1,380,722 355 payments
  5. Amgen Inc. $1,206,118 2 payments
  6. Medical Device Business Services, Inc. $453,776 102 payments
  7. Genentech, Inc. $394,101 35 payments
  8. Inari Medical, Inc. $326,877 245 payments
  9. Stryker Corporation $249,381 209 payments
  10. Janssen Research & Development, LLC $130,007 54 payments
Studies the money was for Research payments · program years 2022–2025
  1. Implementation study on the impact of a clinical decision support system on the diagnosis of osteoporosis after hip or vertebral fragility fractures in postmenopausal women. $1,200,551 1 payment
  2. A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination $1,133,636 7 payments
  3. NCT06707688--Abbott Medical - VERITAS Study $896,526 23 payments
  4. Discovery of factors influencing referral of patients diagnosed with atrial fibrillation (AF) to an electrophysiologist (EP) and evaluating ablation patterns using real-world evidence from a community-based healthcare system. $375,791 22 payments
  5. Spyral Affirm $372,604 38 payments
  6. Simplaafy $368,309 60 payments
  7. NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation $312,331 29 payments
  8. A Prospective, Multi-Center, Randomized Controlled Pivotal Study to Evaluate the Safety and Effectiveness of TRUFILLn-BCAEmbolization of the Middle Meningeal Arteryfor the Treatment of Subdural Hematoma $263,460 60 payments
  9. Tiragolumab Tecentriq VS Durvalumab in Unresectable Stage III Nsclc $254,000 2 payments
  10. Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for treatment of the Paroxysmal Atrial Fibrillation $247,353 68 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record